Pacira BioSciences, Inc. PCRX
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +40.65%
- 1 year
- +70.25%
- Open
- 36.41
- Prev close
- 36.39
- Mkt cap
- 1.45B
- Vol
- 810.93K
- Avg vol
- 1.26M
- EPS
- 0.35
- P/E
- 104.00
- Div yield
- 0.00%
More statistics
- Low
- 36.38
- High
- 36.41
- Forward P/E
- 10.52
- Beta
- 0.22
- Short ratio
- 1.89
- Inst. own
- 106.63%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 29.06
- 200-d avg
- 24.84
- 1y target
- 33.57
News
2 days ago businesswire.com
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash. Halper…
-
3 days ago benzinga.com
Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr
Viatris Inc. ("Viatris") (NASDAQ:VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to
3 days ago prnewswire.com
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary…
2 weeks ago benzinga.com
Top 3 Health Care Stocks That May Fall Off A Cliff In October
Option Care Health, Pacira Biosciences and HealthStream show overbought RSI levels above 83, warning momentum-focused investors.
-
3 weeks ago benzinga.com
Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5
Truist Securities analyst Anish Nikhanj downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and raises the price target from $31 to $36.5.
-
3 weeks ago benzinga.com
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5
RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $25 to $36.5.
3 weeks ago benzinga.com
This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Analysts downgraded Voya, Pacira, Genworth, and more, with price-target changes for several.
3 weeks ago benzinga.com
CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for HOOD, SAIL, U and CRWD; cut targets for BULL, ALGN and PCRX, with PCRX downgraded to Neutral.
-
3 weeks ago benzinga.com
HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5
HC Wainwright & Co. analyst Douglas Tsao downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Neutral and lowers the price target from $38 to $36.5.
3 weeks ago benzinga.com
Nasdaq Falls Over 300 Points as Oil Prices Surge: Investor Sentiment Weakens, Fear & Greed Index Remains in ‘Fear’ Zone
Markets stayed fearful as index fell to 38; Dow gained, S&P/Nasdaq slipped amid oil surge and Iran tensions. PepsiCo and Pacira shares rose.
-
3 weeks ago benzinga.com
Jefferies Downgrades Pacira BioSciences to Hold, Announces $36 Price Target
Jefferies analyst Glen Santangelo downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and announces $36 price target.
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Pacira BioSciences (NASDAQ:PCRX) shares moved upwards by 44.0% to $36.3 during Thursday's regular session. The company's market cap stands at $1.0 billion. Onconetix (NASDAQ:ONCO) stock rose…
3 weeks ago benzinga.com
Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
Pacira BioSciences stock surges 44% after Viatris announces a $1.65 billion takeover deal to expand its pain treatment portfolio.
3 weeks ago benzinga.com
Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings
U.S. stocks fell Thursday as Nasdaq slid 150+ points; energy rallied, healthcare dropped. PepsiCo beat estimates but cut FY26 outlook; oil jumped 5%.
3 weeks ago benzinga.com
Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday
U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira soared 44.1% on Viatris acquisition news.
-
3 weeks ago benzinga.com
Truist Securities Maintains Buy on Pacira BioSciences, Raises Price Target to $31
Truist Securities analyst Les Sulewski maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $30 to $31.